Health News
More Hormone, More Risk
People with chronic kidney disease are at risk of deadly heart problems. If their kidneys stop functioning entirely, they have to go on dialysis. How can doctors spot kidney patients at risk of these complications?
Three-Day Dialysis Isn't Enough
Most kidney failure patients get dialysis treatment three times a week, often taking off the weekend. These two-day breaks may not be such a good idea.
Kidney Failure? Keep Treating Your Lupus
Lupus is a disease that can harm many parts of the body, and even end up causing kidney failure. Researchers have found a way to improve the survival of these patients.
Detecting Dialysis Risk
Doctors need to know which kidney disease patients are at risk for complications. Can they take action before those problems arise? The trouble is figuring out who is at risk. A specific hormone may be the sign.
The Color of Dialysis
For some time, studies have suggested that African-Americans do better on dialysis than whites. Such findings have affected practices guiding who gets kidney transplants. Now, those practices may need to change.
Seeing Sudden Death on Dialysis
When a diabetes patient's kidneys fail, that patient has to be put on dialysis. These patients may be at risk of having their heart suddenly stop. Now, researchers have found a way to spot who is most at risk.
Staying Alive after a Kidney Transplant
Kidney disease patients can wait years before they get a transplant. Even when they get a new organ, their body might reject it. Now, there is a way to make patient's bodies more accepting of transplants.
Low Blood Pressure During Dialysis May Lead to Clots
It's been known that low blood pressure while undergoing kidney dialysis is linked to some nasty side effects. Now the risk of blood clots has been added to that expanding list.
FDA: Modified dosing recommendations for Erythropoiesis-Stimulating Agents
The U.S. Food and Drug Administration (FDA) is informing healthcare professionals of modified recommendations for more conservative dosing of erythropoiesis-stimulating agents ( ESAs ) in patients with chronic kidney disease (CKD) to improve the safe use of these drugs.
FDA Alert For Nulojix
Bristol-Myers Squibb (BMS) informed healthcare professionals about the risk evaluation and mitigation strategy ( REMS ) that is required for Nulojix to ensure that the benefits of Nulojix outweigh the risks of post-transplant lymphoproliferative disorder ( PTLD ) and progressive m ultifocal l eukoencephalopathy ( PML ), both of which can be fatal.